Literature DB >> 12658800

Effects of platelet factor 4 on expression of bone marrow heparan sulfate in syngenic bone marrow transplantation mice.

Fankai Meng1, Hanying Sun, Wenli Liu, Huiling Yuan, Huizhen Xu, Lan Sun, Yinli Zhou, Tianhua Ren.   

Abstract

To explore the effects of platelet factor 4(PF4) on hematopoietic reconstitution and its mechanism in syngenic bone marrow transplantation (BMT). The syngenic BMT mice models were established. 20 and 26 h before irradiation, the mice were injected 20 micrograms/kg PF4 or PBS twice into abdominal cavity, then the donor bone marrow nuclear cells (BMNC) were transplanted. On the 7th day, spleen clone forming units (CFU-S) were counted. On the 7th, 14th and 21st day after BMT, the BMNC and megakaryoryocytes in bone marrow tissue were counted and the percentage of hematopoietic tissue and expression level of heparan sulfate in bone marrow tissue were assessed. In PF4-treated groups, the CFU-S counts on the 7th day were higher than those in BMT groups after BMT. The BMNC and megakaryoryocyte counts and the percentage of hematopoietic tissue and heparan sulfate expression level were higher than those in BMT group on the 7th, 14th and 21st day after BMT (P < 0.01 or P < 0.05). PF4 could accelerate hematopoietic reconstitution of syngenic bone marrow transplantation. The promotion of the heparan sulfate expression in bone marrow may be one of mechanisms of PF4.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12658800     DOI: 10.1007/BF02828176

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  7 in total

Review 1.  Specificities of heparan sulphate proteoglycans in developmental processes.

Authors:  N Perrimon; M Bernfield
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

2.  [Platelet factor 4, reversible inhibitor of megakaryocytogenesis, protector of megakaryocytes during chemotherapy].

Authors:  J P Caen; X Xi; S Aidoudi; S Fournier; N Schlegel; S Bellucci; Z C Han
Journal:  Bull Acad Natl Med       Date:  1995-11       Impact factor: 0.144

3.  Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins.

Authors:  P Gupta; T R Oegema; J J Brazil; A Z Dudek; A Slungaard; C M Verfaillie
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

4.  Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents.

Authors:  Z C Han; M Lu; J Li; M Defard; B Boval; N Schlegel; J P Caen
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

5.  Glycosaminoglycans enhance megakaryocytopoiesis by modifying the activities of hematopoietic growth regulators.

Authors:  Z C Han; S Bellucci; Z X Shen; J P Maffrand; M Pascal; M Petitou; J Lormeau; J P Caen
Journal:  J Cell Physiol       Date:  1996-07       Impact factor: 6.384

6.  Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche.

Authors:  P Gupta; T R Oegema; J J Brazil; A Z Dudek; A Slungaard; C M Verfaillie
Journal:  Blood       Date:  1998-12-15       Impact factor: 22.113

7.  Direct and reversible inhibition of platelet factor 4 on megakaryocyte development from CD34+ cord blood cells: comparative studies with transforming growth factor beta1.

Authors:  X Xi; J P Caen; S Fournier; N Schlegel; J Amiral; O Sibony; P Blot; Z C Han
Journal:  Br J Haematol       Date:  1996-05       Impact factor: 6.998

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.